A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Top Cited Papers
- 26 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 584 (7819), 120-124
- https://doi.org/10.1038/s41586-020-2381-y
Abstract
An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.This publication has 33 references indexed in Scilit:
- A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike proteinCell Research, 2015
- Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyondTrends in Microbiology, 2015
- Clinical Care of Two Patients with Ebola Virus Disease in the United StatesThe New England Journal of Medicine, 2014
- Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization DetectionJournal of Visualized Experiments, 2011
- Features and development of CootActa crystallographica. Section D, Structural biology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa crystallographica. Section D, Structural biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa crystallographica. Section D, Structural biology, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor associationProceedings of the National Academy of Sciences of the United States of America, 2004